BMYBristol-Myers SquibbRunning, no new patients
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
Clear Cell Renal Cell Carcinoma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 681 (final count)
- Started
- May 21, 2021
- Main results expected
- Jul 29, 2025
- Fully finished
- May 10, 2027
- Results posted
- Sep 22, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale
Measured over: Pre-dose (Day 1 to Day 28)
Adjusted Geometric Mean of Nivolumab Trough Serum Concentration at Steady State (Cminss) on Original Scale
Measured over: Pre-dose (Day 1 to Day 28)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04810078 · record last updated 2026-09-22 · checked 2026-11-09 15:47 UTC